Advertisement

Search Results

Advertisement



Your search for Matthew Stenger matches 162 pages

Showing 151 - 162


leukemia

Phase II Trial of Ponatinib Shows Activity in Heavily Pretreated CML and Philadelphia Chromosome–Positive ALL

On October 31, 2013, Ariad Pharmaceuticals, the manufacturer of ponatinib, agreed to an FDA request to suspend marketing and sales of the drug due to the risk of life-threatening blood clots and severe narrowing of blood vessels. The FDA states that it will continue to evaluate ponatinib to further ...

leukemia

Sequential Addition of Gemtuzumab Ozogamicin to Standard Chemotherapy of No Benefit in Older Patients With Newly Diagnosed AML

In a phase III trial (EORTC [European Organisation for Research and Treatment of Cancer]/GIMEMA [Gruppo Italiano Malattie Ematologiche dell’Adulto] consortium AML-17 trial) reported in the Journal of Clinical Oncology, Sergio Amadori, MD, of Tor Vergata University Hospital in Rome, and...

leukemia

Study Assesses Frequency of Allogeneic Hematopoietic Cell Transplantation in Patients With AML in First Complete Remission

In a study reported in Journal of Clinical Oncology, Raya Mawad, MD, of Fred Hutchinson Cancer Research Center, and colleagues assessed the frequency of allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia (AML) in first complete remission at their institution and...

leukemia

Flow Cytometric Residual Disease Highly Prognostic in Older AML Patients

Older patients with acute myeloid leukemia (AML) have a high relapse rate after standard chemotherapy. In a study reported in Journal of Clinical Oncology, Sylvie D. Freeman, MD, PhD, of University Hospitals Birmingham National Health Service Trust, and colleagues investigated whether assessing...

leukemia

Flow Cytometric Minimal Residual Disease Highly Prognostic in AML Patients Aged Under 60

In a study reported in Journal of Clinical Oncology, Monique Terwijn, PhD, of the VU University Medical Centre in Amsterdam, and colleagues assessed the prognostic performance of flow cytometric minimal residual disease detection in acute myeloid leukemia (AML) patients aged < 60 years. They...

leukemia

FLT3 Inhibitor Quizartinib Shows Activity in Relapsed/Refractory AML

Internal tandem duplications (ITDs) in the FMS-like tyrosine kinase 3 (FLT3) juxtamembrane region are observed in 20% to 30% of patients with acute myeloid leukemia (AML), and point mutations in the FLT3 activation loop are observed in 5% to 10%. FLT3-ITD mutations are associated with early relapse ...

leukemia

Study Determines Optimal Chemotherapy Regimen for Younger Patients With AML

In a study (Medical Research Council AML 15 Trial) reported in Journal of Clinical Oncology, Alan K. Burnett, MD, of Cardiff University School of Medicine and colleagues compared induction with daunorubicin/cytarabine, daunorubicin/cytarabine plus etoposide, and fludarabine/cytarabine/granulocyte...

issues in oncology
leukemia

Risk-Directed Treatment Intensification Significantly Improves Outcomes in Children With ALL and Intrachromosomal Amplification of Chromosome 21

In a study reported in Journal of Clinical Oncology, Anthony V. Moorman, PhD, of Newcastle University, and colleagues compared outcomes in children and adolescents with B-cell precursor acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21) in a trial in...

issues in oncology
leukemia

Intrachromosomal Amplification of Chromosome 21 Associated With Poor Outcome in Children With ALL

Intrachromosomal amplification of a region of chromosome 21 (iAMP21; three or more extra copies of RUNX1 on an abnormal chromosome 21) is a recently identified recurrent genomic abnormality associated with poorer outcome in acute lymphoblastic leukemia (ALL). In a study reported in Journal of...

leukemia

No Benefit/Detriment of New Donor in Second Hematopoietic Stem Cell Transplantation for Leukemia Relapse

Minimal data are available on outcomes of second allogeneic hematopoietic stem cell transplantation from unrelated donors after first hematopoietic stem cell transplantation in patients with hematologic relapse of acute leukemia. In a study reported in Journal of Clinical Oncology, Maximilian...

leukemia

Lugano 2013: Ibrutinib Highly Active in Patients with Chronic Lymphocytic Leukemia with 17p Deletion

The 17p deletion in chronic lymphocytic leukemia (CLL) is associated with worse outcome in patients receiving standard chemotherapy. The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has shown durable antitumor activity in high-risk CLL. Adrian Wiestner, MD, PhD, of the National...

hematologic malignancies
leukemia

High Rate of Durable Remissions with BTK Inhibitor Ibrutinib in Patients with Relapsed Chronic Lymphocytic Leukemia

Durable remissions are uncommon with current treatments for relapsed chronic lymphocytic leukemia (CLL). Bruton’s tyrosine kinase (BTK) is an essential component of B-cell receptor signaling that mediates interactions with the tumor microenvironment and promotes survival and proliferation of...

Advertisement

Advertisement



Advertisement